SPC changes (Exelon, Ganfort, Ozurdex)
Exelon (rivastigmine; Novartis) can caused dose-related gastrointestinal disorders, including diarrhoea. Patients who show symptoms of dehydration resulting from prolonged vomiting or diarrhoea can be managed with intravenous fluids and dose reduction or discontinuation of treatment according to the updated summary of product characteristics.
Ganfort (bimatoprost, timolol maleate; Allergan) should be administered at least five minutes apart from other topical ophthalmic medicines.
Ozurdex (dexamethasone; Allergan) is now indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. Increased intraocular pressure, cataracts and conjunctival haemorrhage are listed as very common (=1/10) adverse events when Ozurdex is used for this indication. Common adverse reactions (=1/100 to <1/10) include migraine, retinal detachment, visual impairment and eyelid pruritus.
Citation: The Pharmaceutical Journal URI: 11081016
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now